Immatics (Group)

https://www.immatics.com

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. The Company’s transformative product candidates are ? best in class ? Adoptive Cell Therapies and Bispecific TCR molecules. These products are directed against tumor targets that have been identified and validated by Immatics’ proprietary and world-leading XPRESIDENT® technology. XPRESIDENT® is the most sensitive, unbiased and high-throughput technology capable of identifying targets in virtually any type of cancer and any HLA type. Together with Immatics’ powerful TCR discovery technology XCEPTOR®, these two platforms allow a full range of cancer therapies to be developed. Immatics’ pipeline includes T-cell therapy programs based on the proprietary ACTolog®, ACTengine®and ACTallo® approaches, which are developed in collaboration through Immatics US with University of Texas MD Anderson Cancer Center and co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT), and several bispecific TCR and antibody molecules. Operating from Tuebingen, Munich (Germany) and Houston (Texas), the Company has recognized that novel, better and safer targets are the key to developing future cancer immunotherapies and it is Immatics’ mission to deliver the power of T cells to cancer patients. *

	Start	2000-09-01 splitoff
	Today	Immatics Biotechnologies GmbH
	Predecessor	University of Tübingen (Eberhard-Karls-Universität)
	Industry	cancer drug
	Industry 2	ACTengine® cell therapy product
	Person	Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
	Person 2	Christ, Arnd (Immatics 202010– CFO before InflaRx + Proteros + MediGene + NovImmune + Probiodrug + Hoechst)

	Region	Tübingen
	Country	Germany
	Street	15 Paul-Ehrlich-Str.
	City	72076 Tübingen
	Tel	+49-7071-5397-0
		Address record changed: 2020-12-12

Basic data	Employees	E: 501 to 1,000 (2023-12-31)
	Currency	EUR
	Annual sales	53,997,000 (revenue, consolidated (2023) 2023-12-31)
	Profit	-96,994,000 (2023-12-31)
	Cash	425,895,000 (2023-12-31)

		* Document for »About Section«: Immatics Biotechnologies GmbH. (7/8/19). "Press Release: Immatics Appoints Harpreet Singh as Chief Executive Officer". Tübingen & Houston, TX.

		Record changed: 2024-06-07